Two snakebite antivenoms have potential to reduce Eswatini's dependency upon a single, increasingly unavailable product: Results of preclinical efficacy testing.

• Autori principali: Stefanie K Menzies (Autore), Thea Litschka-Koen (Autore), Rebecca J Edge (Autore), Jaffer Alsolaiss (Autore), Edouard Crittenden (Autore), Steven R Hall (Autore), Adam Westhorpe (Autore), Brent Thomas (Autore), James Murray (Autore), Nondusimo Shongwe (Autore), Sara Padidar (Autore), David G Lalloo (Autore), Nicholas R Casewell (Autore), Jonathan Pons (Autore), Robert A Harrison (Autore)
• Natura: Libro
• Pubblicazione: Public Library of Science (PLoS), 2022-09-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

<h4>Background</h4>Snakebite is a major public health concern in Eswatini, where treatment relies upon one antivenom-SAIMR Polyvalent. Although effective in treating snakebite, SAIMR Polyvalent is difficult to source outside its manufacturing country (South Africa) and is dauntingly expe...